<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1255">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04542980</url>
  </required_header>
  <id_info>
    <org_study_id>CVDTRS001</org_study_id>
    <nct_id>NCT04542980</nct_id>
  </id_info>
  <brief_title>Qualitative Evaluation of Tear Fluid and Blood for Auto Antibodies Produced in Response to COVID-19</brief_title>
  <official_title>Qualitative Evaluation of Tear Fluid and Blood for IgM and IgG Produced in Response to SARS-CoV2, the Virus Responsible for COVID-19.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Namida Lab</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Namida Lab</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study objective is to collect tear and blood samples from individuals with positive
      SARS-COV2 diagnosis and test those samples for the presence of various SARS-COV2 viral
      antigens and autoantibodies.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Qualitative assessment of IgM and/or IgG by indirect ELISA assay.</measure>
    <time_frame>through study completion, up to 8 months</time_frame>
    <description>Determination of the presence or absence of IgM and/or IgG autoantibodies in response to SARS-CoV2 infection. In the case of presence, concentration may be determined as well.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>SARS-CoV 2 Infection</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>SARS-CoV2 Positive</arm_group_label>
    <description>Tear Samples: Tear samples will be collected from 100 patients who have tested positive for the SARS-CoV2 virus.
A total of 100 Blood samples will be drawn using standard phlebotomy techniques for venipuncture from patients who have tested positive for the SARS-CoV2 virus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Control tear and serum samples will be selected from Namida Lab's own biorepository.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>SARS-CoV2 Autoantibody detection</intervention_name>
    <description>Through the data collected from this study we hope to support the development of an ELISA assay for the detection of IgM and IgG autoantibodies produced in response to the presence of SARS-CoV2</description>
    <arm_group_label>SARS-CoV2 Positive</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tears and Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study participants will be recruited from hospital and health care settings testing and/or
        treating individuals for the presence of the SARS-CoV2 virus and resulting COVID-19
        disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older Has been tested for SARS-CoV2 and awaiting results Sample
             collection for SARS-CoV2 testing Tested positive for SARS-CoV2 virus (confirmed by
             RT-PCR) prior to enrollment

        Exclusion Criteria:

          -  Under 18 years of age Concurrent eye infection or trauma unrelated to presence of
             SARS-CoV2 virus. Advanced COVID-19 state what would preclude safe and feasible sample
             collection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Daily, PhD</last_name>
    <phone>479-334-2828</phone>
    <email>anna@namidalab.com</email>
  </overall_contact>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 13, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2020</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoantibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>Supporting information can be obtained by making a request to the central study contact.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

